Related Experiment Video
Updated: Oct 21, 2025
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
11.1K
Factors affecting survival in elderly patients with diffuse large B-Cell lymphoma
Bahar Uncu Ulu1, Tuğçe Nur Yiğenoğlu1, Semih Başcı1
1Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey.
Leukemia Research
|September 4, 2021
Summary
Elderly patients with diffuse large B cell lymphoma (DLBCL) face poorer prognoses. Early relapse and failure to achieve remission significantly impact survival in older DLBCL patients.
Area of Science:
- Oncology
- Hematology
- Clinical Medicine
Background:
- Diffuse large B cell lymphoma (DLBCL) incidence increases in elderly patients, correlating with poorer survival outcomes compared to younger individuals.
- Identifying specific prognostic factors in elderly DLBCL patients is crucial for effective clinical management and treatment strategies.
Purpose of the Study:
- To analyze the clinical outcomes of elderly DLBCL patients.
- To identify key factors influencing survival in DLBCL patients aged 65 years and older in a real-world setting.
Main Methods:
- Retrospective evaluation of 330 DLBCL patient data, stratified into three age groups: <65, 65-79, and ≥80 years.
- Analysis focused on factors affecting survival in patients aged 65 and above, including relapse rates and response to first-line chemotherapy.
Main Results:
- Patients aged 80 and older experienced significantly shorter median Progression-Free Survival (PFS) and Overall Survival (OS) compared to the 65-79 age group.
- A high proportion of elderly patients (≥80 years) relapsed within 12 months of first-line treatment (84.6%).
- Early relapse, failure to achieve complete remission (CR), and high International Prognostic Index (IPI) scores were significantly associated with poor survival in patients ≥65 years.
Conclusions:
- Advanced age is a significant negative prognostic factor for DLBCL survival.
- Relapse within the first year and incomplete remission after initial treatment are critical indicators of poorer outcomes in elderly DLBCL patients.
- While R-CHOP remains standard, novel therapeutic approaches are needed to improve outcomes for elderly DLBCL patients facing treatment challenges.
Related Concept Videos
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
29
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
29
01:15Drug Dosing: Geriatric Patients
39
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
39
01:21Cancer Survival Analysis
481
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
481
01:22Bioavailability: Influencing Factors
61
Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...
61
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
31
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
31
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
93
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
93